甲状腺功能亢进症患者血清抵抗素水平与血糖、血脂及甲状腺激素的关系

The relationship between serum resistin level and blood sugar, blood lipids and thyroid hormone in patients with hyperthyroidism

目的探讨甲状腺功能亢进症（简称甲亢）患者血清抵抗素水平与血糖、血脂、甲状腺激素（TH）的关系。方法甲亢组50例，来源于2008、2009年就诊于哈医大二院内分泌科患者．均为新确诊尚未服药病例；以同时间到医院体检的40例健康者为对照组，两组均排除糖尿病、肥胖、高血压、高血脂。ELISA法测定血清抵抗素水平；化学发光法测定空腹胰岛素、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）；葡萄糖氧化酶一过氧化物酶（GOD—PAP）法测定空腹血糖；胆固醇氧化酶法测定总胆固醇（T—CH）；磷酸甘油氧化酶（GPO）法测定甘油三酯（TG）；均相酶比色法测定高密度脂蛋白胆固醇（HDL—C）、低密度脂蛋白胆固醇（LDL-C）。同时测定身高、体重、腰围、臀围，计算体重指数（BMI）、胰岛素抵抗指数（HOMA—IR）。组间比较采用t检验，相关分析采用Pearson相关检验，用多元逐步回归方法比较抵抗素与血糖、血脂、TH的关系。结果甲亢组血糖[（5．2±0．7）mmoL／L]、抵抗素[（132．1±41．3）μg／L]、FTIj[（19．8±8．7）pmol／L]、n[（54．1±29．6）pmol／L]、胰岛素[（7．9±2．8）mU/L]、胰岛素抵抗指数[（2．3±1．0）]明显高于对照组[（4．7±0．5）mmol／L，（65．1±5．9）μg／L、（4．1±0．6）pmol／L、（14．3±2．2）pmol／L、（6．4±2．7）mU／L、（1．5±1．2）；t值分别为4．64、10．17、11．42、8．49、4．48、9．42，P〈0．01或〈0．05]。甲亢组T—CH[（3．7±0．8）mol／L]、LDL—C[（1．8±0．6）mol／L]、TSH[（0．01±0．01）mU／L]明显低于对照组[（4．6±0．7）mol／L、（2．3±0．7）mol／L、（1．80±0．90）mU／L；￡值分别为5．30、3．33、14．48，P均〈0．01）]。相关分析显示，甲亢组抵抗素与FT3、FT4、HOMA—IR呈正相关（r=0．719、0．790、0．396，P〈0．01或〈0．05），与T—CH、LDL负相关（r=-0．364、-0．519，P〈0．05或〈0．01）。多元逐步回归显示，甲亢组抵抗素与n、n、HOMA—IR正相关（r=0．756，P均〈0．01）。结论抵抗素水平的调节受甲状腺激素影响，甲亢患者血抵抗素可能与胰岛素抵抗及糖脂代谢紊乱有关。

Objective To undertake a controlled, prospective study to investigate the relationship between serum resistin level and blood sugar, blood hpids and thyroid hormone in patients with hyperthyroidism. Methods Clinical data of 50 patients with hyperthyriodism were collected from 2008 to 2009 in department of endocrinology the Second Hospital of Harbin Medical University. All patients were newly diagnosed cases that received no medication. At the same time, 40 healthy persons underwent physical examination in the hospital were taken as control group. Diabetes, obesity, hypertension, and high cholesterol were excluded from the two groups. Serum resistin level was determined using ELISA method. Chemiluminescence was used to check the levels of fasting insulin, free triiodothyronine （FT3）, free thyroxin（FT4）, and thyroid stimulating hormone （TSH）. Glucose oxidase method determination-peroxidase-anti-peroxidase（GOD-PAP） was used to check the levels of fasting blood-glucose. Cholesterol oxidase method was used to check the levels of total cholesterol（T-CH）. Glycerol-phosphate oxidase was used to check the levels of triglyceride（TG）. Enzymes colorimetric method was used to check high density level of lipoprotein cholesterol （HDL-C） and low density level of lipoprotein cholesterol （LDL-C）, and the height, weight, waist circumference, and hip circumference were measured. Body mass index（BMI） and insulin resistance index（HOMA-IR） were calculated. Groups were compared using t test and correlation analysis using Pearson correlation test, and the relationship between serum resistin level and blood sugar, blood lipids and thyroid hormone were analyzed using multiple linear stepwise regression analysis method. Results Serum glucose [ （5.2 ± 0.7）mmol/L ], resistin concentrations[（132.1 ±41.3）μg/L], FF3[（19.8 ± 8.7） pmol/Ll, FT4[（54.1± 29.6）pmol/L], fasting insulin levels[（7.9 ± 2.8）mU/L] and HOMA-IR（2.3 ＋ 1.0） were significantly higher compared with controls group [（4.7 ± 0.5）mmol/L, （65.1 ±5.9）μg/L, （4.1 ±0.6）pmolfL, （14.3 ± 2.2）pmol/L, （6.4 ± 2.7）mU/L, （1.5 ± 1.2） ; t = 4.64, 10.17, 11.42, 8.49, 4.48, 9.42, P 〈 0.01 or 〈 0.05） ]. T-CH [ （3.7 ± 0.8） mol/L ], LDL-C [ （ 1.8± 0.6）mol/L], TSH[ （0.01 ± 0.01）mU/L] were significantly lower compared with controls group[ （4.6± 0.7）moL/L, （2.3 ± 0.7）moL/L, （1.80 ± 0.90）mU/L; t = 5.30, 3.33, 14.48; all P 〈 0.01）]. Pearson correlation analysis showed that resistin and FT3, FT4 and HOMA-IR was positively correlated, respectively （r = 0.719, 0.790, 0.396, P 〈 0.01 or 〈 0.05）, resistin and T-CH and LDL was negatively correlated, respeetively（r = - 0.364, - 0.519, P 〈 0.05 or 〈 0.01 ）. Multiple linear regression analysis showed that resistin and FT3, FT4, and HOMA-IR was positively correlated, respectively（r = 0.756, P 〈 0.01 ）. Conclusion Resistin and FT3 and FF4 are related. Resistin might play important roles in insulin resistance and glucose and lipid metabolism disorders in patients with hyperthyriodism.